Sichuan Kelun-Biotech Biopharmaceutical stock
6990.HKHKSESichuan Kelun-Biotech Biopharmaceutical Co., Ltd., HealthcareISIN CNE1000062J1
49Score 49 out of 100, Weak
Price and trend
65 / 100
Price history
+5.9% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 0.2% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 16% below its 52-week high. Largest decline in 3 years: 40% (October 2025 to March 2026).
Chart figures for advanced users
- SMA 50$58.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$58.02
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$44.17
- The lowest closing price of the last twelve months.
- Resistance$68.86
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. belongs to the Biotechnology industry (China) and, with a market value of $13.9B, is number 25 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $308.61M (up 6.5% year on year) and a loss of $57.28M.
- MEQIRI Score 49 out of 100 (Weak): rank 383 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $45.05, with the price 29% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 183.6% a year since 2021, Biotechnology median 19.7%.Growth 70
- Analysts expect strong earnings growthUp 126.3% a year through 2028 (estimates from 19 analysts).Growth 70
- Earnings turn into cashFree cash flow 340% of earnings over the last 12 months.
Weaknesses
- DilutionShare count up 149% since 2021.Capital allocation 26
- Volatile share priceVolatility 52% a year over the last 12 months.Stability 57
Its standout strength is growth, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $32.18 and expensive above $75.08 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $86.36 (cash-flow model) and $3.73 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.5%. At 9.5% the fair value would be $37.89, at 7.5% it would be $55.04.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (45.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 42.1% on the twelve months before. Revenue has grown strongly since 2021, at around 184% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 72%, operating −23%, net −19%. Last 12 months: net 6%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 29 Mar 2027in 136 days
- Last reported
- 17 Aug 2026EPS reported 0.24 (expected 0.03)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 4.3% since 28 Oct 2026.
- Earnings per share
- 0.36+4.3%
- Revenue
- $457.43M−0.5%
- Earnings per share
- 2.9−2.9%
- Revenue
- $772.5M−0.6%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Sichuan Kelun-Biotech Biopharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- ExelixisEXEL $17.55B90
- Neurocrine BiosciencesNBIX $17.15B77
- Jazz PharmaceuticalsJAZZ $15.43B66
- BridgeBio PharmaBBIO $15.23B49
- Kymera TherapeuticsKYMR $12.73B45
- Madrigal PharmaceuticalsMDGL $12.44B33
- Pharmaron Beijing300759.SZ $12.15B58
- Summit TherapeuticsSMMT $12.03B34
ETFs that hold Sichuan Kelun-Biotech Biopharmaceutical
Held by 42 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS Solactive China Technology UCITS ETF USD accUIC2 | 0.54% | 0.47% | €254.2M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.39% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.35% | 0.40% | €813.42M |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.23% | 0.30% | €132.6M |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.19% | 0.65% | €73.86M |
| Franklin FTSE China UCITS ETFFLXC | 0.16% | 0.19% | €1.43B |
| Xtrackers MSCI China UCITS ETF 1CXCS6 | 0.15% | 0.65% | €1.51B |
| Xtrackers MSCI Emerging Markets ESG UCITS ETF 1CXZEM | 0.07% | 0.25% | €1.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 12 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.